Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients.
about
High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial.An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myelomaMyeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report.Novel approaches to the treatment of primary amyloidosis.An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trialAmyloidosis: pathogenesis and new therapeutic options.Ten-year follow-up after autologous stem cell transplantation of a patient with immunoglobulin light-chain (AL) amyloidosis with deposits in the heart, liver and gastrointestinal tract.Long term results of heart transplantation in patients with amyloid heart disease.Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patientsAntibody-mediated resolution of light chain-associated amyloid deposits.High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience.Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?Drug Insight: emerging therapies for amyloidosis.Amyloidosis and the lung.Perspectives in treatment of AL amyloidosis.Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego).Myocardial infarction with "clean coronaries" caused by amyloid light-chain AL amyloidosis: a case report and literature review.Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis.Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.Light-chain amyloidosis: SCT, novel agents and beyond.Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.Recent advances in the diagnosis and management of cardiac amyloidosis.Amiloidosis, a mysterious disease, still underestimated.The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation.Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis.High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases.Autologous stem cell transplant for Al amyloidosis.Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant.Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP.AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation.High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis.Novel combination chemotherapy for primary (AL) amyloidosis myeloma: clinical, laboratory and serum amyloid-P protein scan improvement.Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006.Evaluation of intensive chemotherapy in AL amyloidosis: usefulness of flow cytometric analysis of plasma cells in bone marrow.Guidelines on the diagnosis and management of AL amyloidosis.High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.
P2860
Q31032765-35880151-0085-4C96-BE14-F67217A92F29Q33304297-1F03735F-E289-49B8-B78E-F1FB23C420D0Q33744195-471D63FC-64BF-4D03-90D0-9F5A6E4A97EBQ33860770-099FBD1B-0B82-4E38-B8A4-D95D49FD9E8BQ34075126-553F744B-AF00-4FC6-8F9A-EF5F3393EAD9Q34435465-9DBD0B4B-18D7-47A9-896D-82E5C432B6C4Q35081363-E942C2B5-7E07-4234-8F47-3C1E9F7F136BQ35111771-B7AC1D83-B7CE-4167-872C-6C6984404D58Q35208216-CEA8BDF1-FB2E-4944-9EFD-00F0D028A1FAQ35378115-193CED7A-1388-4C23-AE14-AF39EB7C9946Q35485742-DD5C20DD-1DDF-4A08-AEA9-49A82BD3EE9AQ35745765-0D2529E3-590B-4C03-B23F-9D2FFA04345BQ35750326-5A13EC36-78BA-4754-912C-7E72E0301669Q36215543-CF3A4A89-7B84-45E0-A9B1-5B733E830035Q36484561-FBB47754-D334-4187-ABB1-F867EB3BB1C1Q36577160-EC2D7C6D-20A7-4944-B216-7B48A53A7D0CQ36692876-D98BDEE6-48BE-4E01-9FC6-7BEAB15AEB5AQ37045885-65CF7B0C-7D5B-41F0-9F17-6C5F1B50C065Q37045900-A5DB6481-06E8-4165-8C56-30F72DA2E4FAQ37866798-EEC54CE3-3361-4307-89CE-4ED6FBA4FFCCQ37904673-267E3EB7-E5E2-4405-AB9C-C0E2B5177A95Q37995198-CC25031A-8213-4204-B3C4-EEDA1B9787D8Q38056010-4EC5737F-19C8-4A0F-8BC0-C49A10922C80Q38100588-706002C9-C38F-4F09-871C-4465B717A4D9Q38171831-A0D62D3C-CC1C-49BD-824C-A432AE29D20CQ40109481-2B5EB2BA-6A05-4945-9932-B2A5CF2B15D4Q40252288-2F73C605-D693-4863-B30D-0ACEABEA4C95Q40287459-CDB87266-F7F9-465D-B243-CE7E8985E05CQ41021929-5DC9A55F-58A4-41B5-9029-B7862FD84A57Q42179759-CF103EA3-7063-4769-B15A-14136DED7A6DQ42879120-BC214D72-63E3-42FC-BF6A-B44B4433B1DDQ43936667-977F197D-034C-4346-874B-CB27F2A1CA81Q44199471-1B2089DE-2D46-48B3-9B84-21019E044C2DQ44210765-3D0EC9C2-0AC7-453B-AFCA-3ADE50239453Q44461630-FCDC9FBE-CB19-4BC3-9CF1-0F1E337F2A69Q44468671-C5181549-A217-4A6B-9466-1CF05641EAABQ44778219-50E209A5-ACBE-4549-A64D-DF4E61F2BDA7Q44924110-1FC49BA9-7F59-4477-854C-C6A0A18AD8C3Q45164371-6F657041-59E6-44F3-87C0-F3D6A85C72A3Q47602198-DED57D5E-0950-499E-A51B-1E5DFB83B279
P2860
Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Prognostic factors for surviva ...... osis: a report on 21 patients.
@en
Prognostic factors for surviva ...... osis: a report on 21 patients.
@nl
type
label
Prognostic factors for surviva ...... osis: a report on 21 patients.
@en
Prognostic factors for surviva ...... osis: a report on 21 patients.
@nl
prefLabel
Prognostic factors for surviva ...... osis: a report on 21 patients.
@en
Prognostic factors for surviva ...... osis: a report on 21 patients.
@nl
P2093
P2860
P1476
Prognostic factors for surviva ...... osis: a report on 21 patients.
@en
P2093
Bataille R
Bourquelot P
Harousseau JL
P2860
P304
P356
10.1046/J.1365-2141.1998.00772.X
P407
P577
1998-06-01T00:00:00Z